These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28521651)

  • 21. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.
    Tomasini P; Serdjebi C; Khobta N; Metellus P; Ouafik L; Nanni I; Greillier L; Loundou A; Fina F; Mascaux C; Barlesi F
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis.
    Wu SG; Li H; Tang LY; Sun JY; Zhang WW; Li FY; Chen YX; He ZY
    Tumour Biol; 2017 Jun; 39(6):1010428317705082. PubMed ID: 28653887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
    Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chen YC; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    Lung Cancer; 2016 Aug; 98():99-105. PubMed ID: 27393514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients.
    Haghgoo SM; Khosravi A; Mortaz E; Pourabdollah-Toutkaboni M; Seifi S; Sabour S; Allameh A
    Clin Biochem; 2017 Apr; 50(6):293-300. PubMed ID: 27923629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis.
    Chang WY; Wu YL; Su PL; Yang SC; Lin CC; Su WC
    PLoS One; 2018; 13(2):e0192161. PubMed ID: 29447182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Kashima J; Okuma Y; Miwa M; Hosomi Y
    Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Miliary brain metastases from lung adenocarcinoma with EGFR (L858R) and CTNNB1 mutations.
    Kunishige M; Takeuchi E
    Thorac Cancer; 2023 Dec; 14(34):3419-3420. PubMed ID: 37920971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?
    Wang TJ; Saad S; Qureshi YH; Jani A; Nanda T; Yaeh AM; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Lesser J; Halmos B; Stoopler MB; Lassman AB; Cheng SK; Isaacson SR
    Neuro Oncol; 2015 Jul; 17(7):1022-8. PubMed ID: 25910841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
    Weber B; Winterdahl M; Memon A; Sorensen BS; Keiding S; Sorensen L; Nexo E; Meldgaard P
    J Thorac Oncol; 2011 Jul; 6(7):1287-9. PubMed ID: 21847041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer.
    Stone E; Allen HA; Saghaie T; Abbott A; Daniel R; Mead RS; Kohonen-Corish M; Plit M; Morgan L
    Intern Med J; 2014 Dec; 44(12a):1188-92. PubMed ID: 25228365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.
    Mochizuki S; Nishimura N; Inoue A; Murakami K; Nukiwa T; Chohnabayashi N
    Respir Investig; 2012 Sep; 50(3):117-21. PubMed ID: 23021771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Miliary cerebral carcinomatosis secondary to EGFR mutation-positive lung adenocarcinoma].
    Dumoulin J; Rozensztajn N; Paradis M; Sellier J; Abel A; Giraud P; Labrune S; Chinet T
    Rev Mal Respir; 2016 Jan; 33(1):67-71. PubMed ID: 25794997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring
    Takamori S; Toyokawa G; Shimokawa M; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Mukae N; Hirai F; Tagawa T; Oda Y; Iwaki T; Iihara K; Honda H; Maehara Y
    Anticancer Res; 2018 Jun; 38(6):3731-3734. PubMed ID: 29848735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
    Chonan M; Narita N; Tominaga T
    BMC Res Notes; 2016 Jan; 9():2. PubMed ID: 26724810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
    Porta R; Sánchez-Torres JM; Paz-Ares L; Massutí B; Reguart N; Mayo C; Lianes P; Queralt C; Guillem V; Salinas P; Catot S; Isla D; Pradas A; Gúrpide A; de Castro J; Polo E; Puig T; Tarón M; Colomer R; Rosell R
    Eur Respir J; 2011 Mar; 37(3):624-31. PubMed ID: 20595147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.